Raman Spectroscopy : Theory and Practice. [elektronicky zdroj]

Autor: Szymanski, H. A.

Externí odkaz: Kolekce e-knih KNAV (Registrovani uzivatele: plny text online 5 minut, dalsi pristup na vyzadani. Registered users: full text online 5 minutes, further access on request.)

Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial

Autor: Pepin S., Nicolas J. -F., Szymanski H., Leroux-Roels I., Schaum T., Bonten M., Icardi G., Shrestha A., Tabar C., Van Damme P., Donazzolo Y., Launay O., Schurholz T., Sturm K., Toursarkissian N., Schenkenberger I., Vitale F., Brzostek J., Pajek B., Miszczak-Kowalska E., Khoury R., Grosbois M. -A., Gauby C., Lacroix I., Souzy F., Pandey A., Yandle S., Lupinsky N., Goulet F., Milcamps L., De Sousa J., Lardon M., Lyko V., Blattmann A., Janosczyk H., Samson S., De Bruijn I.

Publikováno v: HUMAN VACCINES & IMMUNOTHERAPEUTICS

A quadrivalent high-dose inactivated influenza vaccine (IIV4-HD) is licensed for adults ≥65y of age based on immunogenicity and efficacy studies. However, IIV4-HD has not been evaluated in adults aged 60–64y. This study compared immunogenicity an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fdf0c49a65fbdbcf7d14b4935d9b244
https://pubmed.ncbi.nlm.nih.gov/35674507

A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults

Autor: Ostergaard, L., Vesikari, T., Absalon, J., Beeslaar, J., Ward, B. J., Senders, S., Eiden, J. J., Jansen, K. U., Anderson, A. S., York, L. J., Jones, T. R., Harris, S. L., O'Neill, R., Radley, D., Maansson, R., Pregaldien, J. -L., Ginis, J., Staerke, N. B., Perez, J. L., Belle-Isle, J, Elfassi, E, Fredette, P, Garfield, H, Girard, G, Lachance, P, Adamkova, E, Bartonova, E, Drazan, D, Dvorakova, J, Kosina, P, Kyjonkova, A, Ruzkova, R, Vitousova, E, Ahonen, A, Forsten, A, Karppa, T, Kokko, S, Lagerstrom-Tirri, Pm, Simila, Jk, Adelt, T, Behre, U, Schwarz, Tf, Castiglia, P, Esposito, S, Ferrera, G, Icardi, G, Brzostek, J, Hasiec, B, Konior, R, Pejcz, J, Szymanski, H, Witor, A, Faust, Sn, Finn, Ah, Heath, Pt, Pollard, Aj, Altamirano, Dd, Ashley CT Jr, Bader, Gf, Bauer GH Jr, Block SL Jr, Brandon, Dm, Davis, Mg, Devalle, O, Egelhof, Rh, Essink, Bj, Fouch, Bb, Fox, Bp, Franklin, Er, Garscadden, Ag, Goswami, Up, Gregory, Dm, Helman, Ll, Houchin, Vg, Howard, Ce, Johnson, Ad, Johnston WH Jr, Jordan, Ca, Kimmel, Ma, Klein, Tr, Krilov, Lr, Labarbera, Ap, Labuda JM II, Latiolais, Tg, Lello, Lg, Lewis, Dh, Ley, Ja, London, Al, Martin, Ms, Mcguire, Mr, Mosteller, Vc, Naccarato, Tr, Nassim, Cg, Rey, Mr, Robbins, Ra, Rouse, Kg, Schear, Mj, Senders, Sd, Shepard, Js, Simpson, Mw, Slandzicki, Aj, Slechta, Sb, Tetrick, Ll, Varman, M, Wadsworth LT III, Ware, Db, White, Jh, Wisman PP Jr, Blouin, F, Dionne, M, Dzongowski, P, Heaton, Kj, Langley, Jm, O'Mahony, Mfj, Powell, Cn, Ward, Bj, Ostergaard, Lj, Haapaniemi, Tl, Paassilta, M, Volanen, Ik, Lepich, T, Smukalska, E, Tarczon, I, Tetiurka, Bm, Domingo, Jd, Morato, Av, Riera, Mt, Sanchez, Ca, Torrell, Jmr, Blumenau, J, Campbell, Ng, Cervantes, Ja, Douglas, Wg, Ensz, Dj, Ervin, Je, Fiel, Tc, Fragoso, Vg, Fried, Dl, Gleason, Gp, Green, Sl, Haggag, Az, Johnson, Ct, Khaira, Rs, Kirstein, Jl, Kravitz, Ae, Lederman, Sn, Marcadis, I, Miller, Ve, Moretti, Jm, Pragalos, Aa, Puopolo, Ad, Rubino, J, Seiden, Dj, Sharp, Sc, Sheldon, Ea, Shockey, Gr, Smith, Wb, Stringer, Jc, Strout, Cb, Studdard, He, Tresser, Njl.

Publikováno v: Ostergaard, L, Vesikari, T, Absalon, J, Beeslaar, J, Ward, B J, Senders, S, Eiden, J J, Jansen, K U, Anderson, A S, York, L J, Jones, T R, Harris, S L, O'Neill, R, Radley, D, Maansson, R, Prégaldien, J-L, Ginis, J, Staerke, N B, Perez, J L & B1971009 and B1971016 Trial Investigators 2017, ' A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults ', The New England Journal of Medicine, vol. 377, no. 24, pp. 2349-2362 . https://doi.org/10.1056/NEJMoa1614474

BACKGROUND: MenB-FHbp is a licensed meningococcal B vaccine targeting factor H-binding protein. Two phase 3 studies assessed the safety of the vaccine and its immunogenicity against diverse strains of group B meningococcus.METHODS: We randomly assign

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b1121172935bc884479a6f09f24ec94
https://doi.org/10.1056/nejmoa1614474

Immunogénicité et tolérance d’un vaccin grippal quadrivalent à haute dose par rapport à un vaccin grippal quadrivalent à dose standard chez des sujets de 60 ans et plus : un essai randomisé de phase III

Autor: Pepin, S., Nicolas, J., Szymanski, H., Leroux-roels, I., Schaum, T., Bonten, M., Icardi, G., Donazzolo, Y., Launay, O., de Bruijn, I.

Publikováno v: In Infectious Diseases Now August 2021 51(5) Supplement:S23-S23

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.